China Medical System Holdings (HK:0867) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
China Medical System Holdings announced the acceptance of their New Drug Application for ruxolitinib phosphate cream, aimed at treating vitiligo, by China’s National Medical Products Administration. The cream showed significant efficacy in a Chinese Real-World Study, outperforming target values with mild to moderate adverse events. This product has potential to help the millions suffering from this chronic autoimmune skin condition in China and has already been made available in Hainan’s Pilot Zone and approved in Macau.
For further insights into HK:0867 stock, check out TipRanks’ Stock Analysis page.
